Amgen and Novartis’ Aimovig, first in its new class of migraine drugs, hit the scene in May. And patients were ready for it: so much so that its makers are now overwhelmed in trying to meet initial interest, according to
read moreSomerset, New Jersey-based CDMO Catalent is continuing its investment and expansion campaign, announcing Tuesday that it will buy Juniper Pharmaceuticals for more than $130 million. More: Catalent extends expansion with 3M deal for Juniper Pharmaceuticals Source: fierce
read moreAs drug pricing moves at the federal level have floundered, state officials have taken matters into their own hands. But Massachusetts is discovering there’s a limit to drug-pricing innovation. More: No, Massachusetts, you can't run a PBM-style Medicaid formulary, feds
read moreGDPR has contributed to a decline in the number of healthcare professionals disclosing payments or benefits from the pharma industry, says the Association of the British Pharmaceutical Industry. More: GDPR behind drop in pharma payment disclosure, says ABPI Source: News
read moreA South Florida contract manufacturer that the CDC said was tied to an outbreak of deadly Burkholderia cepacia has had seven lawsuits filed against it on behalf of patients who were infected by the bacterial virus, including three infants who
read moreUS regulators have assigned a priority review to MSD’s application to market the immunotherapy Keytruda in combination with chemotherapy as a first-line treatment for squamous non-small cell lung cancer (NSCLC). More: US priority review for Keytruda/chemo combo in first-line squamous
read more© 1994 - 2026 B.M. Pharmaceuticals